Uzaras C.Avcıbaşı U.Demiroğlu H.Medine E.İ.Kılçar A.Y.Müftüler F.Z.B.Ünak P.2019-10-272019-10-2720160236-57310236-5731https://doi.org/10.1007/s10967-015-4119-0https://hdl.handle.net/11454/25855The aim of this study is to determine the incorporations of PHT radiolabeled with 131I (131I-PHT) on U-87 MG, Daoy and A549 cancerous cell lines. For this, cold and radio-labeling studies were carried out. The radio-labeling yield of 131I-PHT was obtained about 95 %. Subsequently, cell culture studies were carried out and radio-labeling yields of 131I, 131I-PHT on U-87 MG, Daoy and A549 cancerous cells were investigated. Cell culture studies demonstrated that the incorporation values of 131I-PHT on the three cell lines decreased with increasing radioactivity. Consequently, 131I-PHT may be a good radiopharmaceutical for targeting radionuclide therapy of Central Nervous System Tumors. © 2015, Akadémiai Kiadó, Budapest, Hungary.en10.1007/s10967-015-4119-0info:eu-repo/semantics/closedAccessDaoy and A549 cancerous cell linesDiphenylhydantoinEpilepsyPhenytoinRadiolabelingU-87 MGArticle3071131140Q2